Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer

被引：6

作者：

Chau, Ian ^{[1
,2
]}

Ayers, Dieter ^{[3
]}

Goring, Sarah ^{[3
]}

Cope, Shannon ^{[3
]}

Korytowsky, Beata ^{[4
]}

Abraham, Pranav ^{[4
]}

机构：

[1] Royal Marsden Hosp, London SM2 5PT, England

[2] Royal Marsden Hosp, Surrey SM2 5PT, England

[3] Precis Xtract, Vancouver, BC V6H 3Y4, Canada

[4] Bristol Myers Squibb Co, Lawrenceville, NJ 08648 USA

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2020年 / 9卷 / 02期

关键词：

gastric cancer; nivolumab; propensity scores; real-world evidence; simulated treatment comparison; CHEMOTHERAPY; ATTRACTION-2;

D O I：

10.2217/cer-2019-0145

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To determine the effectiveness of nivolumab compared with routine clinical practice (RCP) for patients with gastric or gastroesophageal cancer refractory to, or intolerant of, two or more previous regimens, using real-world electronic patient records from a US population, a single-arm trial (CheckMate 032) and a randomized controlled trial in an Asian setting (ATTRACTION-2). Materials & methods: A simulated treatment comparison was conducted to predict overall survival for patients treated with nivolumab compared with RCP in the USA. Results: Results of the indirect simulated treatment comparison suggest that nivolumab is associated with a 50% reduction in the risk of all-cause mortality relative to RCP (Hazard ratio: 0.50; 95% CI: 0.36, 0.68). Conclusion: The survival benefit of nivolumab may extend more generally to the USA.

引用

页码：103 / 114

页数：12

共 28 条

[1] Statistics Notes - Interaction revisited: the difference between two estimates
Altman, DG
Bland, JM
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7382): : 219 - 219
[2] A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality
Austin, Peter C.
[J]. MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (01) : 119 - 151
[3] The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement
Benchimol, Eric I.
Smeeth, Liam
Guttmann, Astrid
Harron, Katie
Moher, David
Petersen, Irene
Sorensen, Henrik T.
von Elm, Erik
Langan, Sinead M.
[J]. PLOS MEDICINE, 2015, 12 (10)
[4] Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?
Chau, Ian
[J]. LANCET, 2017, 390 (10111) : 2418 - 2419
[5] Choi J, 2017, J CLIN ONCOL S15, V35, pe15702
[6] Faria R, 2015, NICE DSU technical support document 17. The use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data
[7] FDA, 2017, 125514ORIG1S024 FDA
[8] FDA, 2018, Framework for FDA's Real-World Evidence Program
[9] Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Fuchs, Charles S.
Doi, Toshihiko
Jang, Raymond W.
Muro, Kei
Satoh, Taroh
Machado, Manuela
Sun, Weijing
Jalal, Shadia I.
Shah, Manish A.
Metges, Jean-Phillipe
Garrido, Marcelo
Golan, Talia
Mandala, Mario
Wainberg, Zev A.
Catenacci, Daniel V.
Ohtsu, Atsushi
Shitara, Kohei
Geva, Ravit
Bleeker, Jonathan
Ko, Andrew H.
Ku, Geoffrey
Philip, Philip
Enzinger, Peter C.
Bang, Yung-Jue
Levitan, Diane
Wang, Jiangdian
Rosales, Minori
Dalal, Rita P.
Yoon, Harry H.
[J]. JAMA ONCOLOGY, 2018, 4 (05)
[10] Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a Canadian Cancer Center
Gill, S
Shah, A
Le, N
Cook, EF
Yoshida, EM
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) : 2070 - 2076

← 1 2 3 →